FY2026 EPS Estimates for TSE:ONC Reduced by Zacks Research

Oncolytics Biotech Inc. (TSE:ONC) – Zacks Research cut their FY2026 EPS estimates for shares of Oncolytics Biotech in a research report issued on Thursday, August 27th. Zacks Research analyst D. Bautz now forecasts that the company will post earnings of ($0.37) per share for the year, down from their previous estimate of ($0.33). The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share.

Oncolytics Biotech Price Performance

Shares of ONC opened at C$14.90 on Wednesday. The company has a debt-to-equity ratio of 14.58, a current ratio of 2.88 and a quick ratio of 8.86. Oncolytics Biotech has a 1-year low of C$0.44 and a 1-year high of C$2.08. The stock has a market cap of C$1.50 billion, a PE ratio of -40.27 and a beta of 0.80. The firm has a fifty day moving average price of C$14.90 and a 200 day moving average price of C$14.90.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.